Trials / Terminated
TerminatedNCT06423794
BHV-7000 Open-Label Extension Bipolar Mania Study
A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-7000 | BHV-7000 75 mg taken once daily |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2025-04-25
- Completion
- 2025-04-25
- First posted
- 2024-05-21
- Last updated
- 2025-12-16
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06423794. Inclusion in this directory is not an endorsement.